Loading...
SYRS logo

Syros Pharmaceuticals, Inc.OTCPK:SYRS Voorraadrapport

Marktkapitalisatie US$26.0
Prijs aandeel
US$0.00035
Mijn reële waarde
n.v.t.
1Y-98.6%
7D75.0%
1D
Portefeuillewaarde
​
Bekijk

Syros Pharmaceuticals, Inc.

OTCPK:SYRS Voorraadrapport

Marktkapitalisatie: US$26.0

Syros Pharmaceuticals (SYRS) Aandelenoverzicht

Syros Pharmaceuticals, Inc. is een biofarmaceutisch bedrijf dat zich richt op de ontwikkeling van behandelingen voor hematologische maligniteiten. Meer informatie

Risicoanalyse

De laatste financiële rapporten zijn meer dan een jaar oud

Heeft geen betekenisvolle marktkapitalisatie ( $26 )

Zeer volatiele aandelenkoers in de afgelopen 3 maanden vergeleken met de US markt


SYRS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Syros Pharmaceuticals, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Syros Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoersUS$0.00035
52 Week HoogtepuntUS$0.04
52 Week LaagUS$0.000001
Bèta0
1 maand verandering75.00%
3 maanden verandering75.00%
1 Jaar Verandering-98.61%
3 jaar verandering-99.90%
5 jaar verandering-99.90%
Verandering sinds IPO-99.90%

Recent nieuws en updates

Recent updates

Seeking Alpha • Jul 02

Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout

Summary Syros Pharmaceuticals focuses on developing therapies for myeloid cancers. The main pipeline candidate is tamibarotene, with positive signals in phase 2 trial and a key data readout coming in Q4 2024. Financially, SYRS has $112.2 million in assets, but faces a high cash burn rate and potential need for more financing. Read the full article on Seeking Alpha
Seeking Alpha • Jan 14

Syros Pharmaceuticals: Rising Despite Dilution, A Must Look

Summary Syros Pharmaceuticals is a cancer-focused biotech working on therapies for blood cancer, with a main drug in development. The company's main program is tamibarotene, targeting specific myeloid cancers with high RARA gene expression. Syros has encouraging data from a phase 2 trial and is currently conducting a phase 3 trial, but lack of asset diversification and high risk should be considered. Read the full article on Seeking Alpha
Seeking Alpha • Sep 20

Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders

Summary Syros Pharmaceuticals has recently acquired its peer Tyme Technologies. The sole purpose of the merger was to acquire TYME's cash balance. Concurrently with the merger, the largest shareholders put in an additional $130m into the company at over 30% premium to current prices. This strong vote of confidence from insiders makes SYRS very interesting, especially when shares are below insiders' entry price. SYRS share price has just declined by 17%, presenting an attractive entry point. SYRS now trades materially below net cash while being fully funded to bring development programs to fruition. The merger between Syros Pharmaceuticals (SYRS) and Tyme Technologies (TYME) was announced in the beginning of July and closed last Friday. This opportunity attracted our interest purely from the merger arb perspective but it actually had two angles to it (with the second one being the key point of this article): Pure merger arbitrage play - pretty much till the closing the spread on the merger stood at 20-40% (chart below) and we could not see any real risks in this transaction despite our best efforts to dig something out. Although such a wide spread on a merger with limited risks might seem too-good-to-true, we actually spot similar opportunities quite often in the less analyzed microcap space and cover them on our premium service Special Situation Investing. The merger arb aspect of the transaction has now fully played out, but there is another angle to the story. Another angle of TYME / SYRS transaction is that SYRS is a very well-positioned pharma company with an attractive development portfolio and this merger simply was an opportunity to acquire SYRS at 20-30% discount to the prevailing market prices by buying it through TYME. Now that the merger closed, one can no longer acquire TYME stock with hopes it will convert to SYRS, but luckily enough SYRS is now itself trading materially below the levels of the merger announcement, presenting an equally attractive opportunity as was acquiring it through TYME. Why the wide spread on the merger? Note: You can easily skip to the next section as this one only looks at a strange market inefficiency in these types of situations. TYME/SYRS Merger Spread Despite our attempts to find an explanation for this wide 20-40% spread, we could not find anything. So in the end we concluded that this is one of those micro-cap merger arbitrage situations where the market is simply not paying attention and our research actually gives us an edge. We love these types of opportunities and covered these regularly on Special Situation Investing. The spread on SYRS / TYME merger seemed completely overblown given the short expected closing timeline, persistently cheap SYRS hedging fees and very low risk of merger termination. The merger was basically an equity raise for SYRS. The buyer openly stated that it was interested solely in TYME's net cash position ($60m) to enhance its liquidity and indicated that TYME's existing drug development program will be put on hold. Shareholder approvals seemed guaranteed as around 35% of SYRS and 30% of TYME shares had already been in support. The PIPE financing for an additional $130m from the largest shareholders at a premium to the market prices added further confidence that every single party of the transaction wants this to close successfully. As expected, shareholder approvals were received on the 15th of September and the merger closed a day later. As further proof of market inefficiency in these types of situations, the spread still persisted even after the shareholder approval. After the vote SYRS issued an announcement stating that the merger will close the next day but the spread persisted and even increased slightly to 10%. Only by the end of the day the spread was finally eliminated. What's next for SYRS? Note: post-merger closing, SYRS has effected a 10-to-1 reverse stock split. Further calculations refer to SYRS's share price and count after the split. Aside from raising cash through the merger with TYME, SYRS also simultaneously did a huge $130m PIPE (vs $50m market cap at the time) at $0.94/share ($9.40/share adjusted for the recent split). The participants were mostly major shareholders of the company - large and reputable PE firms including Bain Capital, Invus Public Equities, Ally Bridge MedAlpha, and others. SYRS co-founder and founding investor Flagship Pioneering also participated. The fact that these firms, who have significantly more knowledge and information about the SYRS pipeline have put that much money at over 30% premium to current prices adds significant confidence in the value of the company's current pipeline. It's no secret that biopharma investing is largely a gamble. However, one thing for sure is that such reputable firms do not like throwing good money after the bad, and especially not in this size. Both transactions have now provided SYRS with enough cash runway through 2025. Post-merger, SYRS has 27.9m of outstanding shares and total cash of ~$240m (after deducting transaction expenses). Net cash is at ~$200m or ~$7.16 per SYRS share. SYRS is down 17% on the first day after the merger close and now sits close to an all-time-low at $6.08/share. The stock is currently trading 15% below net cash and over 35% discount to where the largest shareholders have just made a material investment. SYRS Net Cash Before the merger, SYRS used to trade at up to 8-10% discount to net cash. However, right now the company is in much better shape - a very strong cash position and no financing/dilution risk until 2026 - should be enough to advance its main treatment Tamibarotene into commercialization. If Tamibarotene shows good phase 3 results, the upside from current levels will be very material. These points, as well as the recent vote of confidence from major shareholders, suggest that 15% discount to net cash is overly punitive.
Seeking Alpha • Sep 13

Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609

Syros Pharmaceuticals (NASDAQ:SYRS) on Tuesday said the U.S. FDA had granted an orphan drug designation to its inhibitor SY-5609 for the treatment of pancreatic cancer. SY-5609 is currently being assessed in combination with chemotherapy for the treatment of patients with relapsed metastatic pancreatic cancer, SYRS said in a statement. The FDA's orphan drug designation program expedites the development and evaluation of a drug or biological product to prevent a rare disease or condition. SYRS stock +4.5% to $0.80 after hours.
Seeking Alpha • Aug 08

Syros Pharmaceuticals Q2 2022 Earnings Preview

Syros Pharmaceuticals (NASDAQ:SYRS) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.41 (-13.9% Y/Y) and the consensus Revenue Estimate is $4.78M (-7.4% Y/Y). Over the last 1 year, SYRS has beaten EPS estimates 50% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 3 upward revisions and 0 downward. Revenue estimates have seen 0 upward revisions and 1 downward.

Rendement voor aandeelhouders

SYRSUS BiotechsUS Markt
7D75.0%-2.4%0.3%
1Y-98.6%28.3%26.2%

Rendement versus industrie: SYRS presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 28.3 % opleverde.

Rendement versus markt: SYRS presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 26.2 % opleverde.

Prijsvolatiliteit

Is SYRS's price volatile compared to industry and market?
SYRS volatility
SYRS Average Weekly Movement9,829.5%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stabiele aandelenkoers: De aandelenkoers van SYRS is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van SYRS is het afgelopen jaar gestegen van 5009% naar 9830%.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
2011n/an/awww.syros.com

Syros Pharmaceuticals, Inc, een biofarmaceutisch bedrijf, richt zich op de ontwikkeling van behandelingen voor hematologische maligniteiten. De belangrijkste productkandidaten van het bedrijf zijn Tamibarotene, een selectieve retinoïnezuurreceptor alfa agonist, die zich in Fase III van de klinische studie bevindt voor een genomisch gedefinieerde subset van patiënten met myelodysplastisch syndroom en Fase II van de klinische studie voor patiënten met acute myeloïde leukemie; SY-2101, een nieuwe orale vorm van arseentrioxide voor de behandeling van patiënten met acute promyelocytische leukemie; en SY-5609, een cycline-afhankelijke kinase 7-remmer, die zich in een Fase I klinische studie bevindt bij patiënten met geselecteerde vergevorderde vaste tumoren. Het bedrijf was voorheen bekend als LS22, Inc. en veranderde zijn naam in Syros Pharmaceuticals, Inc. in augustus 2012.

Syros Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Syros Pharmaceuticals zich tot de beurswaarde?
SYRS fundamentele statistieken
MarktkapitalisatieUS$26.00
Inkomsten(TTM)-US$97.81m
Inkomsten(TTM)US$386.00k
0.0x
P/S-verhouding
0.0x
Koers/Winstverhouding

Is SYRS overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SYRS resultatenrekening (TTM)
InkomstenUS$386.00k
Kosten van inkomstenUS$88.64m
Brutowinst-US$88.25m
Overige uitgavenUS$9.56m
Inkomsten-US$97.81m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)0
Brutomarge0.00%
Nettowinstmarge0.00%
Schuld/Eigen Vermogen Verhouding0.0%

Hoe presteerde SYRS op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/06/03 17:42
Aandelenkoers aan het einde van de dag2026/06/03 00:00
Inkomsten2024/09/30
Jaarlijkse inkomsten2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Syros Pharmaceuticals, Inc. wordt gevolgd door 4 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Mark BreidenbachOppenheimer & Co. Inc.
Zegbeh JallahRoth Capital Partners
Philip NadeauTD Cowen